213 related articles for article (PubMed ID: 37231509)
21. Identification of circRNAs involved in the development of hepatocellular carcinoma after insufficient radiofrequency ablation.
Chen JW; Lai LS; Luo JY; Zhou CR; Li MG; Huang MS; Wu P
Neoplasma; 2022 May; 69(3):527-537. PubMed ID: 35144476
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.
Liu X; Ren H; Guo H; Wang W; Zhao N
Clin Exp Immunol; 2021 Feb; 203(2):219-229. PubMed ID: 33030251
[TBL] [Abstract][Full Text] [Related]
23. A well-matched marriage of immunotherapy and radiofrequency ablation to reduce the relapse and progression of hepatocellular carcinoma.
Liao R; Song P; Duan Y; Ye W; Yin K; Kang M; Yu Y; Yang J; Tang W
Biosci Trends; 2022 Nov; 16(5):377-380. PubMed ID: 36089338
[TBL] [Abstract][Full Text] [Related]
24. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.
Chew V; Lai L; Pan L; Lim CJ; Li J; Ong R; Chua C; Leong JY; Lim KH; Toh HC; Lee SY; Chan CY; Goh BKP; Chung A; Chow PKH; Albani S
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5900-E5909. PubMed ID: 28674001
[TBL] [Abstract][Full Text] [Related]
25. Effect of RFA and TACE combined with postoperative cytokine-induced killer cell immunotherapy in primary hepatocellular carcinoma.
Ji Q; Fu Y; Zhu X; Wang L; Ling C
J BUON; 2021; 26(1):235-242. PubMed ID: 33721457
[TBL] [Abstract][Full Text] [Related]
26. Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression.
Chen X; Huang Y; Chen H; Chen Z; Chen J; Wang H; Li D; Su Z
J Nanobiotechnology; 2022 Jan; 20(1):34. PubMed ID: 35033089
[TBL] [Abstract][Full Text] [Related]
27. Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages.
Ng CKY; Dazert E; Boldanova T; Coto-Llerena M; Nuciforo S; Ercan C; Suslov A; Meier MA; Bock T; Schmidt A; Ketterer S; Wang X; Wieland S; Matter MS; Colombi M; Piscuoglio S; Terracciano LM; Hall MN; Heim MH
Nat Commun; 2022 May; 13(1):2436. PubMed ID: 35508466
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance.
Cao S; Lyu T; Fan Z; Guan H; Song L; Tong X; Wang J; Zou Y
Cancer Imaging; 2022 Jan; 22(1):2. PubMed ID: 34983650
[TBL] [Abstract][Full Text] [Related]
29. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection.
Feng Y; Wu H; Huang DQ; Xu C; Zheng H; Maeda M; Zhao X; Wang L; Xiao F; Lv H; Liu T; Qi J; Li J; Zhong N; Wang C; Feng H; Liang B; Ren W; Qin C; Nguyen MH; Zhu Q
Eur Radiol; 2020 Nov; 30(11):6357-6368. PubMed ID: 32529568
[TBL] [Abstract][Full Text] [Related]
30. Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress.
Thompson SM; Callstrom MR; Jondal DE; Butters KA; Knudsen BE; Anderson JL; Lien KR; Sutor SL; Lee JS; Thorgeirsson SS; Grande JP; Roberts LR; Woodrum DA
PLoS One; 2016; 11(9):e0162634. PubMed ID: 27611696
[TBL] [Abstract][Full Text] [Related]
31. Sublethal heat treatment of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent manner.
Tan L; Chen S; Wei G; Li Y; Liao J; Jin H; Zou Y; Huang M; Peng Z; Guo Y; Peng S; Xu L; Kuang M
Cancer Lett; 2019 Sep; 460():29-40. PubMed ID: 31173855
[TBL] [Abstract][Full Text] [Related]
32. Dynamic changes of phenotype and function of natural killer cells in peripheral blood before and after thermal ablation of hepatitis B associated hepatocellular carcinoma and their correlation with tumor recurrence.
Wang HY; Cui XW; Zhang YH; Chen Y; Lu NN; Bai L; Duan ZP
BMC Cancer; 2023 May; 23(1):486. PubMed ID: 37254046
[TBL] [Abstract][Full Text] [Related]
33. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling.
Zhang N; Wang L; Chai ZT; Zhu ZM; Zhu XD; Ma DN; Zhang QB; Zhao YM; Wang M; Ao JY; Ren ZG; Gao DM; Sun HC; Tang ZY
PLoS One; 2014; 9(12):e115949. PubMed ID: 25542041
[TBL] [Abstract][Full Text] [Related]
34. Radiofrequency ablation triggers the migration of hepatocellular carcinoma cells by suppressing miR-148a-5p.
Wang H; Cao Y; Hu K; Li Q; Yang Y; Wang L; Qin X; Qiao B; Cheng L; Li P; Dui W
Biol Chem; 2020 Jul; 401(8):985-994. PubMed ID: 32142478
[TBL] [Abstract][Full Text] [Related]
35. The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion.
Peng Z; Wu X; Li J; Pang H; Zhang Y; Lin M; Wang Z; Xiao H; Li B; Chen M; Feng S; Kuang M; Chen S
Int J Hyperthermia; 2022; 39(1):688-696. PubMed ID: 35469522
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.
Mizukoshi E; Yamashita T; Arai K; Sunagozaka H; Ueda T; Arihara F; Kagaya T; Yamashita T; Fushimi K; Kaneko S
Hepatology; 2013 Apr; 57(4):1448-57. PubMed ID: 23174905
[TBL] [Abstract][Full Text] [Related]
37. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
38. Exploring the impact of insufficient thermal ablation on hepatocellular carcinoma: NDST2 overexpression mechanism and its role in facilitating growth and invasion of residual cancer cells.
Wan W; Guo D; Kang T; Pang J; Pan Y; Chen J; Liao W; Chen Y; Lin P; Li L; Yang H; He Y
Int J Hyperthermia; 2024; 41(1):2353309. PubMed ID: 38749506
[TBL] [Abstract][Full Text] [Related]
39. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
[TBL] [Abstract][Full Text] [Related]
40. Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma.
Liao H; Du J; Wang H; Lan T; Peng J; Wu Z; Yuan K; Zeng Y
J Hematol Oncol; 2021 Dec; 14(1):205. PubMed ID: 34895304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
